Laekna Acquires Exclusive WW Rights of Two Oncology Clinical Stage Candidates from Novartis

 Laekna Acquires Exclusive WW Rights of Two Oncology Clinical Stage Candidates from Novartis

Laekna Acquires Exclusive WW Rights of Two Oncology Clinical Stage Candidates from Novartis

Shots:
  • Agreement involves the two oral pan-Akt kinase inhibitors afuresertib (ASB183) and uprosertib (UPB795) with >10 clinical Ph1/2 tested for cancer
  • Accordingly, Novartis will acquire equity stake in Laenka adding upfront fees and milestones including royalties
  • A second agreement b/w them in addition CFG920(CYP17 inhibitor) licensing, an oral androgen inhibitor, for prostate cancer

Click here to read full press release/ article | Ref: US FDA | Image: Crunchbase

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post